SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009, a highly selective small molecule CDK9 inhibitor, currently under Phase 1 clinical trials. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.

SELLAS Life Sciences Group, Inc.

Solstice Minerals Limited ( ($AU:SLS) ) has provided an announcement. Solstice Minerals has released an investor presentation outlining general inf...

Solstice Minerals updates investors on copper-gold exploration profile and disclosures

In a report released today, Paul Howard CFA from Canaccord Genuity maintained a Buy rating on Solstice Minerals Limited, with a price target of A$2...

Canaccord Genuity Keeps Their Buy Rating on Solstice Minerals Limited (SLS)

Solstice Minerals Limited ( ($AU:SLS) ) has issued an update. Solstice Minerals Limited has reported the lapse of 212,959 performance rights that w...

Solstice Minerals Reports Lapse of Performance Rights

SELLAS Life Sciences Group ( ($SLS) ) has issued an update. On July 24, 2026, a sole arbitrator at the Hong Kong International Arbitration Centre d...

SELLAS Life Sciences Faces Adverse Arbitration Ruling

Solstice Minerals Limited ( ($AU:SLS) ) just unveiled an update. Solstice Minerals Limited has issued 180,366 unquoted performance rights under its...

Solstice Minerals Issues New Unquoted Performance Rights Under Incentive Plan

The latest announcement is out from Solesence ( ($SLSN) ). On July 6, 2026, Solésence, LLC entered into a Settlement Agreement with Refy Beauty Ltd...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	SLS	$12.01	+2.65%	5.12M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	SLS	$12.01	+2.6%	5.12M
3
4
5
6

SLS

SLS

Get SELLAS Life Sciences Group, Inc. Data in Excel

Get SELLAS Life Sciences Group, Inc. Data in Excel